SLA Pharma is a niche biopharmaceutical company, specializing in gastrointestinal and allied disorders, with products in clinical development and already approved for human use. SLA Pharma is committed to improving the range of products available to treat gastrointestinal diseases worldwide. SLA Pharma AG is one of the few pharmaceutical companies in the world focused solely on developing medicines for the prevention and treatment of gastrointestinal (GI) disorders. This commitment to developing solutions for GI disorders has made SLA Pharma a world leader in the field through unrivalled development, medical, regulatory and commercial expertise in its therapeutic areas. We have extensive project experience and expertise in the following disease areas: gastroenterology, dermatology & colorectal oncology. We are currently running and recruiting clinical trials to test the efficacy & safety of: - Ortem to treat Pilonidal sinus disease - Alfa to treat Familial adenomatous polyposis & Ulcerative colitis - Anoheal to treat chronic anal fissures. SLA Pharma has offices in the United Kingdom and Switzerland To learn more, visit us at https://www.slapharma.com/